61 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
.
“Tobacco Party” means any person who:
develops, sells or manufactures tobacco products; or
makes the majority of its profits from the importation
8-K
EX-99.5
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
and, in its capacity as the holder of a majority of the outstanding stock of the Company, controls who serves on the Company’s board of directors
8-K
EX-99.4
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
is a principal stockholder of the Company and, in its capacity as the holder of a majority of the outstanding stock of the Company, controls who serves
8-K
EX-99.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
, approximately 81% of Tenet’s equity interests were held by Sera Medicines, LLC (“Sera Medicines”), which is majority owned by RA Capital Management L.P … used with some success, however the majority of treated patients do not achieve complete remission of their disease. There are currently no drugs
8-K
ELYM
Eliem Therapeutics Inc
26 Jun 24
Submission of Matters to a Vote of Security Holders
4:23pm
of the Share Issuance Proposal required approval by the affirmative vote of (i) a majority in voting power of the votes cast by holders … by this clause (i), the “Baseline Vote”) and (ii) a majority of the aggregate voting power of the outstanding shares of the Company’s common stock entitled
DEFA14A
dbk47p5dnk6qpctop59
14 Jun 24
Additional proxy soliciting materials
5:02pm
8-K
EX-10.1
paxzl9p
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
DEFM14A
o96fai7o gbjk6
4 Jun 24
Proxy related to merger
8:00am
PREM14A
9su7xz1la74
17 May 24
Preliminary proxy related to merger
4:36pm
10-K/A
rvs9sukk9jms0bir0k
29 Apr 24
Annual report (amended)
4:02pm
DEFA14A
lbi8i281t
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-10.5
hjtwqgh2sxj06nbp
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-2.1
fwmt9
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.3
844db4s63a1yu0u
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
d19l55b
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.3
832vvarrfprcgod
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.1
x4ohui7
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.4
xjtti7ps
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am